Serotonin 5-HT<inf>6</inf>receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease

Bellinda Benhamú, Mar Martín-Fontecha, Henar Vázquez-Villa, Leonardo Pardo, María L. López-Rodríguez

Research output: Contribution to journalArticleResearchpeer-review

100 Citations (Scopus)

Abstract

© 2014 American Chemical Society. Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clinical and socioeconomic impact. In the search for novel therapeutic strategies, serotonin 5-HT6receptor (5-HT6R) has been proposed as a promising drug target for cognition enhancement in AD. This manuscript reviews the compelling evidence for the implication of this receptor in learning and memory processes. We have summarized the current status of the medicinal chemistry of 5-HT6R antagonists and the encouraging preclinical findings that demonstrate their significant procognitive behavioral effects in a number of learning paradigms, probably acting through modulation of multiple neurotransmitter systems and signaling pathways. The results of the ongoing clinical trials are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic cognitive impairment in AD, either as stand-alone therapy or in combination with established agents.
Original languageEnglish
Pages (from-to)7160-7181
JournalJournal of Medicinal Chemistry
Volume57
Issue number17
DOIs
Publication statusPublished - 11 Sep 2014

Fingerprint Dive into the research topics of 'Serotonin 5-HT<inf>6</inf>receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this